BBOT: the cashflow

MyFinsight

For the quarter ending 2025-09-30, BBOT had $377,890K increase in cash & cash equivalents over the period. -$72,193K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30
Net loss	-95,247
Depreciation of property and equipment	196
Stock-based compensation	2,927
Fair value of common stock issuable to related party	-7,769
Change in fair value of participation right liability	725
Net accretion of premiums on marketable securities	1,171
Amortization of right-of-use assets	220
Prepaid expense and other currents assets	4,365
Other non-current assets	398
Accounts payble	577
Accrued compensation and benefits	667
Accrued research and development liabilities	15,831
Accrued professional services	480
Operating lease liabilities	74
Other accrued liabilities	-7
Balances due to and from related parties	-62
Net cash used in operating activities	-71,660
Maturities of marketable securities	128,976
Purchases of marketable securities	62,881
Change in related party receivables related to cash pooling arrangement	0
Purchases of property and equipment	533
Net cash provided by (used in) investing activities	65,562
Proceeds from reverse recapitalization and pipe financing	373,457
Payment of deferred transaction costs	11,691
Issuance of series a redeemable convertible preferred stock	0
Issuance of series b redeemable convertible preferred stock, net of issuance costs	22,222
Contribution from bridgebio pharma	0
Net cash provided by financing activities	383,988
Net increase in cash, cash equivalents, and restricted cash	377,890
Cash and cash equivalents at beginning of period	30,983
Cash and cash equivalents at end of period	408,873

Unit: Thousand (K) dollars